Portal de Periódicos da CAPES

Vasopressin receptor antagonism — a therapeutic option in heart failure and hypertension

2000; Wiley; Volume: 85; Issue: s1 Linguagem: Inglês

10.1111/j.1469-445x.2000.tb00031.x

1469-445X

Louise M. Burrell, John Risvanis, Colin I. Johnston, Mareo Naitoh, Leanne C. Balding,

Neuroendocrine regulation and behavior

The precise role of vasopressin in the pathophysiology of cardiovascular disease is controversial, but this peptide hormone is important for several reasons. Firstly, circulating concentrations of vasopressin are elevated in heart failure and some forms of hypertension. Secondly, there is evidence that vasopressin is synthesized not only in the hypophysial‐pituitary axis but also in peripheral tissues including the heart where it acts as a paracrine hormone. Thirdly, vasopressin has vasoconstrictor, mitogenic, hyperplastic and renal fluid retaining properties which, by analogy with angiotensin II, may have deleterious effects when present in chronic excess. Finally, the availability of orally active non‐peptide vasopressin receptor antagonists allows vasopressin receptor antagonism to be considered as a therapeutic option in cardiovascular disease.